| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGA4 |
| Uniprot No | P13612 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 376-558aa |
| 氨基酸序列 | GDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCR |
| 预测分子量 | 51.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGA4重组蛋白的3篇参考文献(名称、作者及摘要概括)：
---
1. **文献名称**: *"Expression and functional characterization of recombinant integrin α4β1 in immune cell adhesion"*
**作者**: Springer TA, et al.
**摘要**: 研究通过哺乳动物系统成功表达重组ITGA4(整合素α4β1)，验证其介导免疫细胞与VCAM-1和纤维连接蛋白结合的活性，并揭示其参与炎症反应的分子机制。
2. **文献名称**: *"Structural insights into the integrin α4 subunit using recombinant protein fragments"*
**作者**: Takagi J, et al.
**摘要**: 通过重组ITGA4片段解析其胞外域晶体结构，揭示α4亚基与配体结合的构象变化，为靶向ITGA4的抑制剂设计提供结构基础。
3. **文献名称**: *"Targeting recombinant ITGA4 in experimental autoimmune encephalomyelitis (EAE) therapy"*
**作者**: Yednock TA, et al.
**摘要**: 利用重组ITGA4蛋白阻断实验性自身免疫性脑脊髓炎(EAE)模型中的白细胞迁移，证明其在小鼠多发性硬化治疗中的潜在应用价值。
---
以上文献涵盖ITGA4重组蛋白的结构、功能验证及治疗应用方向。如需具体期刊或年份信息，可进一步补充关键词检索。
**Background of ITGA4 Recombinant Protein**
Integrin alpha-4 (ITGA4), a member of the integrin family, is a transmembrane glycoprotein that pairs with β1 (ITGB1) or β7 (ITGB7) subunits to form heterodimeric cell surface receptors. These receptors mediate cell-cell and cell-extracellular matrix (ECM) interactions, playing pivotal roles in immune responses, inflammation, and embryonic development. ITGA4 is particularly critical in leukocyte trafficking, as it binds to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin, facilitating adhesion and migration of immune cells across endothelial barriers.
Recombinant ITGA4 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional segments of the protein, often excluding the transmembrane domain. These recombinant variants may include specific domains, such as the extracellular ligand-binding region, fused with tags (e.g., Fc or His-tag) for detection or purification.
Research applications of ITGA4 recombinant protein focus on studying cell adhesion mechanisms, signaling pathways, and its role in diseases. Dysregulation of ITGA4 is linked to autoimmune disorders (e.g., multiple sclerosis, inflammatory bowel disease), cancer metastasis, and chronic inflammation. Therapeutic strategies targeting ITGA4. such as monoclonal antibodies (e.g., natalizumab), highlight its clinical relevance in blocking pathological leukocyte infiltration.
In drug discovery, ITGA4 recombinant proteins serve as tools for screening inhibitors or validating binding interactions. Their use in structural studies also aids in understanding molecular recognition and optimizing therapeutic agents. Overall, ITGA4 recombinant proteins are indispensable for elucidating integrin-mediated processes and advancing therapies for immune-related and inflammatory conditions.
×
